Manni Mohyuddin: My personal preference on T cell redirecting therapy for triple class refractory off trial
Manni Mohyuddin shared a post on X:
“In absence of head to head data, my personal preference on T cell redirecting therapy for triple class refractory off trial:
-slow/indolent relapse: Cilta-cel
-rapid relapse: Elra
Prefer to use talquetamab only after BCMA because it is a very toxic drug that ruins QOL.
Obviously, patient preference reigns supreme. Many will choose bispecifics after hearing the side effects of cilta-cel, which are unpredictable and scary!”
Source: Manni Mohyuddin/X
Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023